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Letters to the Editor
Efficacy and
Safety in Clinical Trials
In their rebuttal to my essay “Efficacy and Safety in Clinical Trials
in Cardiovascular Disease” (1), Granger and McMurray (2) fired a
series of rockets that missed the target.
To criticize previously identified so-called disease markers
(premature ventricular complexes, cardiac output, symptom relief,
plasma norepinephrine) because they do not track with disease
progression is misdirected, because we all agree these are not
fundamental to the disease process. As I have stressed, and
Granger and McMurray seem to agree, structural markers are far
more discriminating. To suggest that not all therapies that slow
disease progression improve outcome is equally disingenuous; that
is why I have stressed that safety as well as efficacy must be
addressed.
Granger and McMurray avoid the real issue. Our treatments are
aimed at slowing or aborting a disease process, but they are
administered to individuals whose well-being is also dependent on
other factors. Granger and McMurray seem interested only in the
net effect. I am interested in separating efficacy from safety. They
defend against such attempts, stating that “using measures of
disease progression . . . [should be] rigorously resisted.”
Rather than hiding behind their self-proclaimed inability to
“understand the disease” or “the exact mechanism of benefit,”
Granger and McMurray would better serve the cardiovascular
community by advocating that mechanisms be carefully addressed
in future clinical trials so as to gain such understanding. Docu-
mentation of the benefit of therapies for early stages of disease
requires assessment of disease progression, and strategies for
management of advanced disease may require separate and perhaps
individualized optimization of efficacy and safety. It is time to
accelerate the learning process, not to retreat into the past comfort
of simple mortality/morbid events trials.
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Reply
We were pleased to see that Dr. Cohn (1) accepts the need to
examine the effect of treatment on mortality, although he
chooses to see this as a measure of safety rather than efficacy.
We do not know how to decide which surrogate measure “tracks
with disease progression.” Dr. Cohn currently favors a structural
marker—a few years ago, norepinephrine or ejection fraction
might have been the popular choice. Who is to say that in a few
more years structural changes will go the same way as those
previous favorites? Moreover, some highly effective treatments
(like implantable cardioverter-defibrillators) do not affect struc-
ture or the disease process but do reduce mortality, underscor-
ing the limitations of predicting treatment effect with disease
markers.
Dr. Cohn’s vision is, of course, utopian. If only we could do
what he wanted—but we have not yet managed to do so and have
failed miserably when we have tried. In the end, however, we agree
with Dr. Cohn’s call to design trials to better understand disease
process and individual response to therapy. He rightly points out
that our ultimate goal of individualized medicine will require much
better understanding of patient response and safety. In doing so,
however, even larger trials will be necessary, and ultimately
measuring important clinical outcomes will always be necessary to
determine the net effect that defines what matters in clinical care.
In the meantime, as long as Dr. Cohn accepts the need for
assessment of “safety,” the debate is more of a philosophical than
practical one—the same large trials with the same clinical out-
comes will be needed.
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Clinical Implications of the
PROTECT–TIMI-30 Trial
We would like to congratulate Gibson et al. (1) for the completion
of the recently reported PROTECT–TIMI-30 (Randomized
Trial to Evaluate the Relative PROTECTion against Post-PCI
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